Summary.-This paper compares anti-leukaemic efficiency with toxicity to the patient of chemotherapy during and immediately after central nervous system irradiation. The drug regimen consisted of daily mercaptopurine (MP) and weekly methotrexate (MTX) at the maximum tolerated dose. Of 140 patients with acute lymphoblastic leukaemia allocated to receive this drug regimen during and after cranial irradiation, 8 died in complete remission within 6 months of the end of irradiation. Details of the nature of these deaths are given. This result led the Working Party to modify the chemotherapy scheduled for this stage in treatment. The modified chemotherapy consisted of MP at reduced dosage before and during cranial irradiation and omission of MP and MTX for 3 weeks after irradiation, during which time daily prednisolone with 2 doses of vincristine were substituted. Following that, the treatment reverted to the original schedule of daily MP and weekly MTX at maximum tolerated dose. Of 109 patients allocated to this modified regimen only one died in remission within 24 weeks after cranial irradiation. Analysis of the anti-leukaemic effect of the modified regimen showed that up to 600 days it was at least as effective as the original more intensive regimen. We conclude that there is a definite advantage in keeping chemotherapy to a minimum during and immediately following cranial prophylactic irradiation.
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WHILE there have been marked improvements in the treatment of acute lymphoblastic leukaemia, the risk of serious infection in patients who have already achieved complete remission has become a matter for concern. Such infections are most often seen in patients who at diagnosis have leucocyte counts below 20 x 109/1 and are less than 14 years old; they comprise about 6000 of all ALL patients and otherwise have a good prognosis (MRC Working Party, 1976 (MRC Working Party, 1975 , 1976 or central nervous system (CNS) irradiation (MRC Working Party, 1977) .
In this paper we report our experience of a treatment protocol, UKALL III given on those days. The oral methotrexate courses in Weeks 15 and 17 were of 3 and 4 daily doses respectively, thereafter all courses were of 5 daily doses. CNS irradiation consisted of a total mid-line dose of 2500 rad to the cranium given by opposing lateral fields, and 1000 rad to the spine measured at the posterior surface of the vertebral bodies. Further details are given in: MRC Working Party (1973) .
(b) UKALL II. 174 patients. The randomized variables analysed were type of CNS irradiation and cyclophosphamide. All patients who achieved remission and who received CNS irradiation are included in this study. All patients received irradiation as a total mid-line dose of 2400 rad given by opposing lateral fields. Of the three CNS prophylaxis groups: (1) received no spinal irradiation but intrathecal MTX as indicated; (2) received 1000 rad to the spine as in UKALL I and intrathecal MTX; (3) received 2400 rad to the spine but no intrathecal MTX. Groups 2 and 3 were randomized to receive cyclophosphamide or not, but all patients in Group 1 received cyclophosphamide. Half the patients stopped chemotherapy after Week 108; the remainder stopped after Week 156. Further details: MRC Working Party (1976). Patients were allocated to UKALL III ordinary only if they had a "good prognosis", (i.e. they were less than 14 years old, presented with a white-cell count of less than 20 x 109/1 and had no radiographic evidence draw n by the Surv-C programme package (Peto et al., 1976 (Peto et al., , 1977 (b) Although some of these fatal infections were due to epidemic illnesses, their variety was too great to make it likely that only abnormal environmental factors were responsible. However, there is a suggestion of a seasonal incidence for the deaths in this trial (Table) . All 
Modification to UKALL III ordinary
As the result of these findings entry to the original UKALL III ordinary protocol was stopped on 17. 11 . 74, and subsequent patients were randomized to one of the two arms of a modified UKALL III ordinary regimen (Fig. I d) . In this, the maximum daily dose of MP before and during cranial irradiation was reduced to 25 mg/M2 and the MP plus MTX treatment of the first 3 weeks after irradiation was replaced by vincristine prednisolone. Amnong the 109 patients who achieved remission and completed irradiation after the protocol had been modified, only one death in remission occurred within one year of starting treatment in Week 24. However, that patient had deviated from the protocol, having received MP in the first 5 weeks, with MTX on the 1st, 3rd and 5th weeks after CNS irradiation. The treatment given, therefore, was similar to the original UKALL IlI ordinary regimen. This patient died from gram-negative septicaemia with retroperitoneal haemorrhage; the neutrophil count was below 0 5 x 109/1 at the onset of infection.
Comparison of the anti-leukaemic effect of original UKALL III ordinary protocol with the modified regimen and with UKALL I and II Fig. 3(a) depicts the disease-free survival in the original and modified regimens. When remission duration is plotted (Campbell et al., 1976) . The second component largely comprises lymphocytes which form rosettes with sheep red cells; this recovers only slowly if at all (Buckton, Court-Brown and Smith, 1967; Stjernsward et al., 1972) .
It may be that the addition of MP to the UKALL III original protocol immediately after CNS irradiation critically delays the recovery of the rapidly repopulating fraction of lymphocytes destroyed by irradiation. In a previous paper (Waller et al., 1977) we showed that MP depressed a small population of lymphocytes which is rapidly replenished when this drug is stopped. These lymphocytes, like the rapidly repopulating radiation-sensitive pool, include K cells and many surface-immunoglobulin-positive cells. In that paper we produced indirect evidence that this MP-sensitive population of lymphocytes might be important as defence against viral infections. If this is the explanation for the early deaths, the timing may have been as important as the total dose of MP in the early deaths.
Other factors might also have been important. For example, lung infection is the most striking common feature of the early fatal infections, and perhaps the UKALL III original treatment caused transient lung damage which predisposed to a variety of infections. Neutrophils may also have been prevented from normal recovery by the UKALL III therapy, for in all the first 5 cases (Table) terminal neutropenia was marked. However, pyogenic infection was not prominent in this series.
It is also possible that lack of familiarity with the original UKALL III may have contributed to these early remission deaths, since 5 occurred in patients admitted in the first 4 months of the trial and only 3 in the latter 91 months. It is revealing to read the reports from St Jude, Memphis, where a consistent factor of the protocols has been the administration of daily MP 50 mg/M2, and weekly MTX during and after CNS irradiation (Simone et al., 1975) . The desirability of reducing doses during irradiation is emphasized in their report of Protocol V7I (Aur et al., 1972) . They write "Radiotherapy was administered in full dosage in all but four patients. All four entered in the early months of the study. They received only 700-1200 rad cranio-spinal irradiation because of severe pancytopenia, fever or infection. In subsequent patients, continuation chemotherapy was reduced more readily during radiotherapy, and this problem was averted."
It seems, therefore, from the Memphis experience and our own, that intensive chemotherapy during and immediately after CNS irradiation is likely to result in serious infection. Our data indicate that relatively gentle chemotherapy during this period has no disadvantage in terms of anti-leukaemic effect, while it is associated with far less toxicity. 
